Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Proportion of abortive hemangioma among infantile hemangioma |
Proportion of abortive hemangioma among infantile hemangioma |
baseline |
|
Secondary |
To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex |
Compare sex predominance between infantile hemangioma and abortive hemangioma |
baseline |
|
Secondary |
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity |
Compare prematurity rates between infantile hemangiomas and abortive hemangiomas |
baseline |
|
Secondary |
To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight |
Compare birthweight between infantile hemangiomas and abortive hemangiomas |
baseline |
|
Secondary |
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization |
Compare localization between infantile hemangiomas and abortive hemangiomas |
baseline |
|
Secondary |
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment |
le hemangiomas and abortive hemangiomaCompare treatment between infanti |
baseline |
|
Secondary |
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : complications |
Compare complications between infantile hemangiomas and abortive hemangioma |
baseline |
|
Secondary |
To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : size |
Compare size (focal, extended or segmental) between infantile hemangiomas and abortive hemangioma |
baseline |
|
Secondary |
To study the evolution of abortive hemangioma : erythematous macule |
Evaluation of the fading of erythematous macule between the stage of maximal proliferation and the last follow-up |
through study completion, an average of 4 years |
|
Secondary |
To study the evolution of abortive hemangioma : papules of proliferation |
Evaluation of the regression of the papules of proliferation between the stage of maximal proliferation and the last follow-up |
through study completion, an average of 4 years |
|
Secondary |
To study the evolution of abortive hemangioma : telangiectasias |
Evaluation of the fading of telangiectasias between the stage of maximal proliferation and the last follow-up |
through study completion, an average of 4 years |
|
Secondary |
To study the evolution of abortive hemangioma : halo of vasoconstriction |
Evaluation of the fading of the vasoconstricted halo between the stage of maximal proliferation and the last follow-up |
through study completion, an average of 4 years |
|
Secondary |
To study the evolution of abortive hemangioma : areas of vasoconstriction |
Evaluation of the fading of vasoconstricted areas between the stage of maximal proliferation and the last follow-up |
through study completion, an average of 4 years |
|
Secondary |
To study the evolution of abortive hemangioma : dilated veins |
Evaluation of the fading of dilated veins between the stage of maximal proliferation and the last follow-up |
through study completion, an average of 4 years |
|